Earnings DeclineThe company's revenue for 4Q24 declined by 30% YoY, missing the projection of $1.2M.
Financial StrainThe company may need to raise additional capital, highlighting potential financial strain.
Uncertain Regulatory OutcomesThe FDA decision on ICCM’s De Novo Marketing Clearance for a minimally-invasive alternative treatment of early-stage, low-risk breast cancer is uncertain, with no response expected by the end of March.